Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Clear Winner in BMS, Exelixis/Ipsen First-line Renal Cancer Race

Executive Summary

While the CheckMate-214 data on the Opdivo/Yervoy combo made the headlines at ESMO, a closer look at the results show there is plenty of room for Cabometyx to have sizeable market share.

Advertisement

Related Content

PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride
Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well
Bristol's Opdivo Delivers, But CheckMate 227 Uncertainties Cloud Quarter
Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel